Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue British Journal of Cancer Année : 2018

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

Résumé

BACKGROUND: Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited toxicity, the recommended phase II dose (RP2D) was only tentatively defined. METHODS: We identified, by MEDLINE search, articles on single-agent trials of mAbs with an FIHT included in our previous survey. For each mAb, we examined tested dose(s) and dose selection rationale in non-FIHTs (NFIHTs). We also assessed the correlation between doses tested in the registration trials (RTs) of all FDA-approved mAbs and the corresponding FIHT results. RESULTS: In the 37 dose-escalation NFIHTs, the RP2D indication was still poorly defined. In phase II-III NFIHTs (n=103 on 37 mAbs), the FIHT RP2D was the only dose tested for five mAbs. For 16 mAbs, only doses different from the FIHT RP2D or the maximum administered dose (MAD) were tested and the dose selection rationale infrequently indicated. In the 60 RTs on 27 FDA-approved mAbs with available FIHT, the FIHT RP2D was tested only for two mAbs, and RT doses were much lower than the FIHT MAD. CONCLUSIONS: The rationale beyond dose selection in phase II and III trials of mAbs is often unclear in published articles and not based on FIHT data.
Fichier principal
Vignette du fichier
bjc2017473.pdf (385.49 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-02292921 , version 1 (02-06-2022)

Licence

Paternité - Pas d'utilisation commerciale - Partage selon les Conditions Initiales

Identifiants

Citer

Marie Viala, Marie Vinches, Marie Alexandre, Caroline Mollevi, Anna Durigova, et al.. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. British Journal of Cancer, 2018, 118 (5), pp.679-697. ⟨10.1038/bjc.2017.473⟩. ⟨hal-02292921⟩
89 Consultations
31 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More